Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. develops clinical-stage therapeutics that modulate lipid-signaling pathways, including programs tied to the endocannabinoid system and fatty acid-binding proteins. Company news commonly covers pipeline updates for ART27.13 and ART26.12, including cancer anorexia-cachexia, neuropathic pain, glaucoma, dermatologic, neurological and other inflammation-related indications.
Recurring developments include FABP5 inhibitor research, peer-reviewed publications, collaborations using biological-data analysis, preclinical and clinical program disclosures, patent activity, and externally funded studies. Artelo news also includes capital-structure actions such as private placements, common stock and warrant offerings, and Nasdaq listing-compliance matters.
Artelo Biosciences, Inc. (NASDAQ:ARTL) will present at the LD 500 Virtual Investor Conference from September 1-4, 2020. CEO Gregory D. Gorgas is scheduled to speak on September 1 at 10:20 a.m. Eastern Time. The presentation will be available via webcast. Artelo is focused on developing therapeutics targeting the endocannabinoid system for conditions like cancer and pain. Attendees can schedule one-on-one meetings with the company through the conference registration platform.
Artelo Biosciences (NASDAQ: ARTL) reported its third-quarter financial results for the period ending May 31, 2020, highlighting progress in its clinical pipeline. The company received a composition of matter patent for its CBD cocrystal, ART12.11, ensuring market exclusivity until 2038. Despite COVID-19 delays, Artelo anticipates starting its Phase 1b/2a study for ART27.13 later this year. Financially, operating expenses rose slightly to $951,395, while the net loss increased to $951,191. Cash reserves decreased to approximately $1.28 million from $4.42 million in the previous year.
Artelo Biosciences (NASDAQ: ARTL) has expanded its license agreement with Stony Brook University to include exclusive rights to third-generation fatty acid binding protein 5 (FABP5) inhibitors. This strategic move aims to enhance its development pipeline for cancer therapeutics and treatments for pain and inflammation. The company plans to identify a lead compound from this new set of inhibitors. Notably, Stony Brook's recent NCI grant offers non-dilutive funding to support these advancements, highlighting the potential for significant value creation through intellectual property protection and partnerships.
Artelo Biosciences (NASDAQ: ARTL) announced its participation in two virtual conferences. Gregory D. Gorgas, CEO, will speak on a panel at BIO Digital on June 8-12, discussing innovative pain management strategies through endocannabinoid modulation. Notably, he will present at the 2020 Virtual Summer Summit on June 9 at 1:35 p.m. Eastern Time. Both events aim to foster networking and share insights on therapeutic developments, with presentations available for on-demand viewing. Artelo focuses on developing treatments addressing unmet medical needs in pain, cancer, and other conditions.
Artelo Biosciences has received a new U.S. patent covering ART12.11, its cocrystal solid form of CBD and TMP, providing intellectual property protection until December 10, 2038. This patent validates the company's strategy in developing novel CBD therapeutics aimed at major health issues like PTSD and inflammatory bowel disease. CEO Gregory D. Gorgas highlighted that the cocrystal approach could enhance drug properties, potentially improving efficacy and safety. Artelo is committed to advancing treatments targeting various diseases through their proprietary therapeutics.